News

YM BioSciences has reported that Cytopia has commenced enrollment of a Phase I/II trial evaluating Cyt387, a potent, orally-administered JAK1/JAK2 inhibitor. The trial is being conducted at Mayo

Merck KGaA has reported that it will be holding its first Pharma Forum on February 23, 2010 in Darmstadt. The focus will be on pharmaceutical excipients. Regulatory authorities

The Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for Biolaxy’s oral insulin project (Nodlin), an innovative insulin formulation to treat

Gilead Sciences and GlaxoSmithKline has announced a licensing agreement to commercialise Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B (HBV) infection in adults in five

Novartis has officially inaugurated the its large-scale flu cell culture vaccine and adjuvant manufacturing facility in Holly Springs, North Carolina. The facility is a result of a partnership

Micromet has entered into an agreement for the process development and manufacture of blinatumomab (MT103) with Lonza. As per the agreement, Lonza is expected to manufacture blinatumomab for

Pharmaceutical Research and Manufacturers of America (PhRMA) has released a new report that US pharmaceutical research and biotechnology companies are testing 97 medicines and vaccines to treat or

Bayer CropScience and GVK Biosciences (GVK BIO) have entered into a research cooperation in the area of early discovery chemistry. The objective is to speed up the search

CardioGenics has provided update on its agreement with Merck Chimie. The company has reported that Merck Chimie is progressing to the next phase of the commercialisation of CardioGenics’